BUDAPEST, HUNGARY, PRINCETON, NJ and LONDON–( September 14, 2010) – ThalesNano today reported that the US Patent and Trademark Office (USPTO) has granted a patent for its industry leading H-Cube®, including several aspects of its proprietary underlying technology.
The H-Cube® is a revolutionary flow hydrogenation system developed for use by the pharmaceutical, fine chemical, petrochemical, biotechnology and related industries. The H-Cube® enables safe, fast and cost-efficient hydrogenation with superior yields when compared to conventional methods.
Ferenc Darvas, President and Chairman of ThalesNano, initiator of the H-Cube®, project and one of the inventors of the H-Cube®, said, “We are delighted that the USPTO has granted us full patent approval for the H-Cube®. Since launching the instrument in 2004, it has won the R&D 100 Award and has become a standard research tool, with more than 500 units sold worldwide. It is also very satisfying to receive patent recognition for this disruptive technology.”
“This is important news for ThalesNano and the H-Cube®,” according to Laszlo Urge, CEO of ThalesNano. “Our technology is in 28 countries worldwide, but the United States remains our biggest market, so gaining the legal protection afforded by a US patent is extremely important. We will of course continue to pursue patent protection for the H-Cube® in other geographies.”
About ThalesNano Inc.
ThalesNano is the world leader in bench-top flow chemistry reactors. The company has the widest portfolio of continuous process instruments for the pharmaceutical, biotech, fine chemical, petroleum/biofuel, and education markets. Its R&D 100 award winning H-Cube® and scale-up system H-Cube Mid™ are used in hundreds of laboratories globally and have become the new industry standard for hydrogenation. Within three years from the original introduction of its flagship H-Cube product, 20 out of the top 20 pharmaceutical companies have introduced and adopted the technology.
Contact: email@example.com for more information.